iBio, Inc. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/dce23517-5ac3-4afa-8892-3e7e03ee7323/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2026 | $-35.1M | 2025-07-01 – 2026-06-30 | evidence 0001420720-26-000020 |
| FY 2025 | $-18.6M | 2024-07-01 – 2025-06-30 | evidence 0001558370-25-011888 |
| FY 2024 | $-16.6M | 2023-07-01 – 2024-06-30 | evidence 0001420720-24-000038 |
| FY 2023 | $-29.3M | 2022-07-01 – 2023-06-30 | evidence 0001420720-23-000045 |
| FY 2022 | $-29.7M | 2021-07-01 – 2022-06-30 | evidence 0001420720-23-000045 |
| FY 2021 | $-31.1M | 2020-07-01 – 2021-06-30 | evidence 0001558370-21-012819 |
| FY 2020 | $-14.0M | 2019-07-01 – 2020-06-30 | evidence 0001104659-20-114567 |
| FY 2019 | $-15.8M | 2018-07-01 – 2019-06-30 | evidence 0001144204-19-041659 |
| FY 2018 | $-14.2M | 2017-07-01 – 2018-06-30 | evidence 0001144204-18-049866 |
| FY 2017 | $-14.3M | 2016-07-01 – 2017-06-30 | evidence 0001144204-17-048249 |
| FY 2016 | $-9.9M | 2015-07-01 – 2016-06-30 | evidence 0001144204-16-127993 |
| FY 2015 | $-6.7M | 2014-07-01 – 2015-06-30 | evidence 0001144204-15-059224 |
| FY 2014 | $-3.8M | 2013-07-01 – 2014-06-30 | evidence 0001144204-14-058454 |
| FY 2013 | $-6.7M | 2012-07-01 – 2013-06-30 | evidence 0001144204-13-053105 |
| FY 2012 | $-9.3M | 2011-07-01 – 2012-06-30 | evidence 0001144204-13-053105 |
| FY 2011 | $-9.7M | 2010-07-01 – 2011-06-30 | evidence 0000930413-12-005739 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).